CRO Chiltern goes up on auction block

The global CRO Chiltern International has been put on the auction block, according to a report in The Mail on Sunday. The report says that Chiltern's private equity owners are looking for about £200 million, which would double what they paid for the company. Over the past year the CRO business has been going through a wave of mergers and acquisitions as the industry undergoes a major shakeout. That's created some quick profits for the groups that had been snapping up these companies. Chiltern conducts Phase I-IV studies in dozens of countries. Story

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.